Overexpression of mutant EGFR protein indicates a better survival benefit from EGFR-TKI therapy in non-small cell lung cancer

BACKGROUND: Epidermal growth factor receptor (EGFR) is a novel target for therapy in a subset of non-small cell lung cancer (NSCLC). Tumors with EGFR mutations showed good response to EGFR tyrosine kinase inhibitors (TKIs). We aimed to identify the discriminating capacity of immunohistochemistry (IH...

Full description

Saved in:
Bibliographic Details
Published in:Oncotarget
Main Authors: Ling, Yun, Yang, Xin, Li, Wenbin, Li, Zhuo, Yang, Lin, Qiu, Tian, Guo, Lei, Dong, Lin, Li, Lin, Ying, Jianming, Lin, Dongmei
Format: Artigo
Language:Inglês
Published: Impact Journals LLC 2016
Subjects:
Research Paper
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC5288154/
https://ncbi.nlm.nih.gov/pubmed/27418143
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.10594
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items